Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma ; volume:9 ; number:1 ; day:27 ; month:2 ; year:2019 ; pages:1-10 ; date:12.2019
Scientific reports ; 9, Heft 1 (27.2.2019), 1-10, 12.2019
- Urheber
-
Blum, Agnieszka
Haussmann, Katy
Streitz, Mathias
Schlickeiser, Stephan
Tietze-Buerger, Carola
Blau, Igor Wolfgang
Uharek, Lutz
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-019-39631-2
- URN
-
urn:nbn:de:101:1-2019031720222396185881
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Blum, Agnieszka
- Haussmann, Katy
- Streitz, Mathias
- Schlickeiser, Stephan
- Tietze-Buerger, Carola
- Blau, Igor Wolfgang
- Uharek, Lutz
- SpringerLink (Online service)
Ähnliche Objekte (12)
Use of marrow scintigraphy to confirm compensatory marrow rather than active myeloma
Use of marrow scintigraphy to confirm compensatory marrow rather than active myeloma
Minimal residual disease in multiple myeloma: current status
Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma
Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment
Measurable residual disease in multiple myeloma: ready for clinical practice?
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
Bone marrow stromal cells dictate lanosterol biosynthesis and ferroptosis of multiple myeloma
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
Use of marrow scintigraphy to confirm compensatory marrow rather than active myeloma
Use of marrow scintigraphy to confirm compensatory marrow rather than active myeloma
Minimal residual disease in multiple myeloma: current status
Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma
Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment
Measurable residual disease in multiple myeloma: ready for clinical practice?
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
Bone marrow stromal cells dictate lanosterol biosynthesis and ferroptosis of multiple myeloma
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
Use of marrow scintigraphy to confirm compensatory marrow rather than active myeloma
Use of marrow scintigraphy to confirm compensatory marrow rather than active myeloma
Minimal residual disease in multiple myeloma: current status
Radiomics analysis of bone marrow biopsy locations in [18F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma
Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment
Measurable residual disease in multiple myeloma: ready for clinical practice?
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
Bone marrow stromal cells dictate lanosterol biosynthesis and ferroptosis of multiple myeloma
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma